FH-006

Phase 3Small molecule

JJiangsu HengRui Medicine Co., Ltd.

FH-006 is one of 82 small molecule programs targeting Recurrent or Metastatic. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent or MetastaticNot yet recruiting

Malignant Solid TumorRecruiting

Lung CancerRecruiting

Malignant Solid TumorsRecruiting

Recurrent or MetastaticPhase 3

Not yet recruiting

Malignant Solid TumorPreclinical

Recruiting

Lung CancerPhase 2

Recruiting

Malignant Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Phase 3

10 2

Abraxane

Bristol-Myers Squibb

Phase 3

7 3

Ilaris

Novartis

Phase 3

2 4

Verzenio

Eli Lilly

Phase 3

2 5

Lynparza

AstraZeneca

Phase 3

2 6

Zepzelca

Jazz Pharmaceuticals

Phase 3

2 7

Tarlatamab-Dznl

Amgen

Phase 3

2 8

DATROWAY

Daiichi Sankyo

Phase 3

2 9

Hycamtin

MMeitheal

Phase 3

6 10

Cytoxan

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

PreclinicalRecruiting

Malignant Solid Tumor

NCT07136142

Q4 2027

Phase 1/2Recruiting

Malignant Solid Tumors

NCT06735144

Q4 2028

Phase 2Recruiting

Lung Cancer

NCT07241767

Q2 2029

Phase 3Not yet recruiting

Recurrent or Metastatic

NCT07790380

Clinical

Trials by Indication[1]

Malignant Solid Tumors1 trial

Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 1/2·NCT06735144·200 enrolled

Lung Cancer1 trial

A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT07241767·200 enrolled

Malignant Solid Tumor1 trial

A Multicenter, Open Label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of FH-006 for Injection in Patients With Malignant Solid Tumors

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Preclinical·NCT07136142·150 enrolled

Recurrent or Metastatic1 trial

A Randomized, Open-label, Multicenter, Phase III Study of FH-006 Versus Investigator's Choice of Chemotherapy in Patients With Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma Who Have Failed Prior PD-1/PD-L1 Inhibitor Combined With Platinum-Based Chemotherapy.

Not yet recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT07790380·480 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for FH-006. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FH-006 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FH-006. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu HengRui Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu HengRui Medicine Co., Ltd.

FH-006

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Q4 2028

Q2 2029

Trials by Indication[1]

Malignant Solid Tumors1 trial

Lung Cancer1 trial

Malignant Solid Tumor1 trial

Recurrent or Metastatic1 trial

References

Drug Info

Quick Facts

Related News